25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NanoViricides Inc
Buy, Hold or Sell?

Let's analyze Nanoviricides together

I guess you are interested in NanoViricides Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NanoViricides Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about NanoViricides Inc

I send you an email if I find something interesting about NanoViricides Inc.

1. Quick Overview

1.1. Quick analysis of Nanoviricides (30 sec.)










1.2. What can you expect buying and holding a share of Nanoviricides? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.82
Expected worth in 1 year
$0.58
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.24
Return On Investment
-18.2%

For what price can you sell your share?

Current Price per Share
$1.34
Expected price per share
$1.1 - $1.58
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Nanoviricides (5 min.)




Live pricePrice per Share (EOD)
$1.34
Intrinsic Value Per Share
$-3.41 - $-1.27
Total Value Per Share
$-2.59 - $-0.45

2.2. Growth of Nanoviricides (5 min.)




Is Nanoviricides growing?

Current yearPrevious yearGrowGrow %
How rich?$11.4m$19m-$7.1m-60.0%

How much money is Nanoviricides making?

Current yearPrevious yearGrowGrow %
Making money-$2m-$2.1m$76.7k3.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Nanoviricides (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#619 / 954

Most Revenue
#814 / 954

Most Profit
#307 / 954

Most Efficient
#168 / 954
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Nanoviricides?

Welcome investor! Nanoviricides's management wants to use your money to grow the business. In return you get a share of Nanoviricides.

First you should know what it really means to hold a share of Nanoviricides. And how you can make/lose money.

Speculation

The Price per Share of Nanoviricides is $1.34. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nanoviricides.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nanoviricides, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.82. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nanoviricides.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-12.6%-0.15-11.1%-0.19-14.0%-0.18-13.1%-0.16-12.0%
Usd Book Value Change Per Share0.064.3%-0.06-4.6%-0.15-11.0%0.000.2%-0.03-2.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.064.3%-0.06-4.6%-0.15-11.0%0.000.2%-0.03-2.3%
Usd Price Per Share1.72-1.31-1.29-2.83-2.05-
Price to Earnings Ratio-2.55--2.20--2.08--4.45--3.59-
Price-to-Total Gains Ratio29.52--4.20--6.51--7.01--14.33-
Price to Book Ratio2.09-1.55-0.95-2.26-1.50-
Price-to-Total Gains Ratio29.52--4.20--6.51--7.01--14.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.34
Number of shares746
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.00
Usd Total Gains Per Share-0.060.00
Gains per Quarter (746 shares)-45.492.31
Gains per Year (746 shares)-181.969.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-182-19209-1
20-364-3740188
30-546-55602817
40-728-73803726
50-910-92004635
60-1092-110205544
70-1274-128406553
80-1456-146607462
90-1638-164808371
100-1820-183009280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.071.00.01.4%
Book Value Change Per Share1.03.00.025.0%1.09.02.08.3%5.012.03.025.0%9.027.04.022.5%24.038.010.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%1.00.071.01.4%
Total Gains per Share1.03.00.025.0%1.09.02.08.3%5.012.03.025.0%9.027.04.022.5%25.038.09.034.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of NanoViricides Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.058-0.061+205%-0.147+353%0.003+1781%-0.031+153%
Book Value Per Share--0.8220.852-4%1.363-40%1.379-40%1.488-45%
Current Ratio--3.6585.276-31%26.018-86%23.255-84%20.512-82%
Debt To Asset Ratio--0.1060.102+4%0.045+136%0.081+31%0.167-37%
Debt To Equity Ratio--0.1190.115+3%0.049+140%0.096+24%0.231-49%
Dividend Per Share----0%-0%-0%-0%
Eps---0.169-0.149-12%-0.187+11%-0.176+4%-0.160-5%
Free Cash Flow Per Share---0.113-0.116+2%-0.111-2%-0.129+14%-0.146+29%
Free Cash Flow To Equity Per Share--0.110-0.060+154%-0.112+202%-0.008+108%4224.799-100%
Gross Profit Margin--1.0001.048-5%1.0000%1.010-1%1.0050%
Intrinsic Value_10Y_max---1.271--------
Intrinsic Value_10Y_min---3.414--------
Intrinsic Value_1Y_max---0.437--------
Intrinsic Value_1Y_min---0.548--------
Intrinsic Value_3Y_max---1.078--------
Intrinsic Value_3Y_min---1.477--------
Intrinsic Value_5Y_max---1.434--------
Intrinsic Value_5Y_min---2.215--------
Market Cap18687104.000-28%23986432.00018268736.000+31%17997145.440+33%39453566.688-39%28597091.408-16%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.630-28%2.0921.549+35%0.950+120%2.255-7%1.496+40%
Pe Ratio-1.983+22%-2.545-2.195-14%-2.081-18%-4.450+75%-3.594+41%
Price Per Share1.340-28%1.7201.310+31%1.291+33%2.829-39%2.051-16%
Price To Free Cash Flow Ratio-2.958+22%-3.797-2.963-22%-2.929-23%-5.315+40%-3.738-2%
Price To Total Gains Ratio22.999-28%29.522-4.203+114%-6.514+122%-7.014+124%-14.334+149%
Quick Ratio--3.5315.100-31%21.597-84%17.607-80%17.563-80%
Return On Assets---0.184-0.158-14%-0.114-38%-0.147-20%-0.114-38%
Return On Equity---0.206-0.175-15%-0.122-41%-0.157-24%-0.132-36%
Total Gains Per Share--0.058-0.061+205%-0.147+353%0.003+1781%-0.031+153%
Usd Book Value--11464077.00011883823.250-4%19011520.250-40%19229218.950-40%20746566.800-45%
Usd Book Value Change Per Share--0.058-0.061+205%-0.147+353%0.003+1781%-0.031+153%
Usd Book Value Per Share--0.8220.852-4%1.363-40%1.379-40%1.488-45%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.169-0.149-12%-0.187+11%-0.176+4%-0.160-5%
Usd Free Cash Flow---1579499.000-1618016.750+2%-1554366.250-2%-1793850.300+14%-2041216.200+29%
Usd Free Cash Flow Per Share---0.113-0.116+2%-0.111-2%-0.129+14%-0.146+29%
Usd Free Cash Flow To Equity Per Share--0.110-0.060+154%-0.112+202%-0.008+108%4224.799-100%
Usd Market Cap18687104.000-28%23986432.00018268736.000+31%17997145.440+33%39453566.688-39%28597091.408-16%
Usd Price Per Share1.340-28%1.7201.310+31%1.291+33%2.829-39%2.051-16%
Usd Profit---2355987.000-2073536.500-12%-2150282.750-9%-2625376.550+11%-2340576.700-1%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.058-0.061+205%-0.147+353%0.003+1781%-0.031+153%
 EOD+2 -6MRQTTM+15 -15YOY+14 -155Y+15 -1510Y+12 -18

3.3 Fundamental Score

Let's check the fundamental score of NanoViricides Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.983
Price to Book Ratio (EOD)Between0-11.630
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.531
Current Ratio (MRQ)Greater than13.658
Debt to Asset Ratio (MRQ)Less than10.106
Debt to Equity Ratio (MRQ)Less than10.119
Return on Equity (MRQ)Greater than0.15-0.206
Return on Assets (MRQ)Greater than0.05-0.184
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of NanoViricides Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.284
Ma 20Greater thanMa 501.391
Ma 50Greater thanMa 1001.443
Ma 100Greater thanMa 2001.689
OpenGreater thanClose1.270
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About NanoViricides Inc

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Fundamental data was last updated by Penke on 2024-11-05 14:02:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Nanoviricides earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nanoviricides to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NanoViricides Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--120.2%+120.2%
TTM--210.7%+210.7%
YOY--219.8%+219.8%
5Y--348.0%+348.0%
10Y--473.2%+473.2%
4.3.1.2. Return on Assets

Shows how efficient Nanoviricides is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nanoviricides to the Biotechnology industry mean.
  • -18.4% Return on Assets means that Nanoviricides generated $-0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NanoViricides Inc:

  • The MRQ is -18.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.4%TTM-15.8%-2.6%
TTM-15.8%YOY-11.4%-4.4%
TTM-15.8%5Y-14.7%-1.1%
5Y-14.7%10Y-11.4%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.4%-11.0%-7.4%
TTM-15.8%-11.7%-4.1%
YOY-11.4%-11.3%-0.1%
5Y-14.7%-12.6%-2.1%
10Y-11.4%-14.3%+2.9%
4.3.1.3. Return on Equity

Shows how efficient Nanoviricides is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nanoviricides to the Biotechnology industry mean.
  • -20.6% Return on Equity means Nanoviricides generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NanoViricides Inc:

  • The MRQ is -20.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.6%TTM-17.5%-3.0%
TTM-17.5%YOY-12.2%-5.3%
TTM-17.5%5Y-15.7%-1.8%
5Y-15.7%10Y-13.2%-2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.6%-14.1%-6.5%
TTM-17.5%-15.8%-1.7%
YOY-12.2%-13.8%+1.6%
5Y-15.7%-18.5%+2.8%
10Y-13.2%-19.2%+6.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of NanoViricides Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Nanoviricides is operating .

  • Measures how much profit Nanoviricides makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nanoviricides to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NanoViricides Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--267.8%+267.8%
TTM--313.2%+313.2%
YOY--224.0%+224.0%
5Y--385.5%+385.5%
10Y--498.7%+498.7%
4.3.2.2. Operating Ratio

Measures how efficient Nanoviricides is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NanoViricides Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.631-2.631
TTM-3.412-3.412
YOY-3.299-3.299
5Y-4.788-4.788
10Y-6.538-6.538
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of NanoViricides Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Nanoviricides is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.66 means the company has $3.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NanoViricides Inc:

  • The MRQ is 3.658. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.276. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.658TTM5.276-1.618
TTM5.276YOY26.018-20.742
TTM5.2765Y23.255-17.979
5Y23.25510Y20.512+2.743
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6583.688-0.030
TTM5.2763.875+1.401
YOY26.0184.695+21.323
5Y23.2555.959+17.296
10Y20.5126.274+14.238
4.4.3.2. Quick Ratio

Measures if Nanoviricides is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nanoviricides to the Biotechnology industry mean.
  • A Quick Ratio of 3.53 means the company can pay off $3.53 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NanoViricides Inc:

  • The MRQ is 3.531. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.100. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.531TTM5.100-1.569
TTM5.100YOY21.597-16.497
TTM5.1005Y17.607-12.507
5Y17.60710Y17.563+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5313.117+0.414
TTM5.1003.444+1.656
YOY21.5974.498+17.099
5Y17.6075.922+11.685
10Y17.5636.414+11.149
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of NanoViricides Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Nanoviricides assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nanoviricides to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Nanoviricides assets are financed with 10.6% credit (debt) and the remaining percentage (100% - 10.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NanoViricides Inc:

  • The MRQ is 0.106. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.102. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.106TTM0.102+0.004
TTM0.102YOY0.045+0.057
TTM0.1025Y0.081+0.021
5Y0.08110Y0.167-0.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1060.354-0.248
TTM0.1020.350-0.248
YOY0.0450.310-0.265
5Y0.0810.366-0.285
10Y0.1670.382-0.215
4.5.4.2. Debt to Equity Ratio

Measures if Nanoviricides is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nanoviricides to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.9% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NanoViricides Inc:

  • The MRQ is 0.119. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.115. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.119TTM0.115+0.004
TTM0.115YOY0.049+0.066
TTM0.1155Y0.096+0.019
5Y0.09610Y0.231-0.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1190.393-0.274
TTM0.1150.436-0.321
YOY0.0490.378-0.329
5Y0.0960.451-0.355
10Y0.2310.493-0.262
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nanoviricides generates.

  • Above 15 is considered overpriced but always compare Nanoviricides to the Biotechnology industry mean.
  • A PE ratio of -2.55 means the investor is paying $-2.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NanoViricides Inc:

  • The EOD is -1.983. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.545. Based on the earnings, the company is expensive. -2
  • The TTM is -2.195. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.983MRQ-2.545+0.562
MRQ-2.545TTM-2.195-0.350
TTM-2.195YOY-2.081-0.114
TTM-2.1955Y-4.450+2.255
5Y-4.45010Y-3.594-0.856
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.983-2.169+0.186
MRQ-2.545-2.453-0.092
TTM-2.195-3.147+0.952
YOY-2.081-3.335+1.254
5Y-4.450-6.032+1.582
10Y-3.594-6.597+3.003
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NanoViricides Inc:

  • The EOD is -2.958. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.797. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.963. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.958MRQ-3.797+0.839
MRQ-3.797TTM-2.963-0.834
TTM-2.963YOY-2.929-0.034
TTM-2.9635Y-5.315+2.352
5Y-5.31510Y-3.738-1.577
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.958-3.020+0.062
MRQ-3.797-3.395-0.402
TTM-2.963-3.650+0.687
YOY-2.929-4.541+1.612
5Y-5.315-8.375+3.060
10Y-3.738-9.277+5.539
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Nanoviricides is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.09 means the investor is paying $2.09 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NanoViricides Inc:

  • The EOD is 1.630. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.092. Based on the equity, the company is underpriced. +1
  • The TTM is 1.549. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.630MRQ2.092-0.462
MRQ2.092TTM1.549+0.544
TTM1.549YOY0.950+0.599
TTM1.5495Y2.255-0.707
5Y2.25510Y1.496+0.759
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6301.860-0.230
MRQ2.0922.035+0.057
TTM1.5492.339-0.790
YOY0.9502.391-1.441
5Y2.2553.666-1.411
10Y1.4964.360-2.864
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NanoViricides Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets12,823
Total Liabilities1,359
Total Stockholder Equity11,464
 As reported
Total Liabilities 1,359
Total Stockholder Equity+ 11,464
Total Assets = 12,823

Assets

Total Assets12,823
Total Current Assets4,971
Long-term Assets7,852
Total Current Assets
Cash And Cash Equivalents 4,798
Total Current Assets  (as reported)4,971
Total Current Assets  (calculated)4,798
+/- 173
Long-term Assets
Property Plant Equipment 7,512
Intangible Assets 325
Long-term Assets Other 15
Long-term Assets  (as reported)7,852
Long-term Assets  (calculated)7,852
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,359
Long-term Liabilities0
Total Stockholder Equity11,464
Total Current Liabilities
Accounts payable 376
Other Current Liabilities 983
Total Current Liabilities  (as reported)1,359
Total Current Liabilities  (calculated)1,359
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -139,375
Other Stockholders Equity 150,839
Total Stockholder Equity (as reported)11,464
Total Stockholder Equity (calculated)11,464
+/- 0
Other
Capital Stock0
Cash and Short Term Investments 4,798
Common Stock Shares Outstanding 11,871
Liabilities and Stockholders Equity 12,823
Net Debt -4,798
Net Invested Capital 11,464
Net Working Capital 3,612
Property Plant and Equipment Gross 14,966



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-30
> Total Assets 
0
0
0
2,730
2,073
1,639
1,002
1,350
1,350
2,506
1,890
1,468
1,468
3,141
2,571
3,001
3,001
5,610
4,511
8,992
8,992
11,156
9,858
10,758
10,758
13,561
14,376
15,630
15,630
15,612
17,875
16,408
25,111
22,889
40,950
44,569
49,018
47,605
45,603
44,187
42,299
40,849
38,318
36,633
34,223
31,364
28,580
27,003
25,266
23,726
22,340
18,546
18,546
15,004
15,395
13,449
11,786
11,618
16,528
16,528
23,914
28,085
32,761
30,262
30,262
26,810
25,145
23,495
23,495
20,335
18,577
16,900
15,417
13,402
11,465
12,823
12,82311,46513,40215,41716,90018,57720,33523,49523,49525,14526,81030,26230,26232,76128,08523,91416,52816,52811,61811,78613,44915,39515,00418,54618,54622,34023,72625,26627,00328,58031,36434,22336,63338,31840,84942,29944,18745,60347,60549,01844,56940,95022,88925,11116,40817,87515,61215,63015,63014,37613,56110,75810,7589,85811,1568,9928,9924,5115,6103,0013,0012,5713,1411,4681,4681,8902,5061,3501,3501,0021,6392,0732,730000
   > Total Current Assets 
0
0
0
2,721
2,068
1,622
877
1,225
1,225
2,377
1,728
1,248
1,248
2,332
1,725
2,120
2,120
4,453
3,318
7,457
7,457
9,569
8,286
9,556
9,556
12,422
13,280
14,589
14,589
14,681
16,999
14,522
20,006
17,755
34,604
37,664
41,604
35,494
34,294
31,682
29,644
28,344
25,911
24,382
22,120
19,441
16,743
15,290
13,705
12,286
10,951
7,322
7,322
4,073
4,630
2,825
1,338
1,349
6,437
6,437
13,986
18,487
23,231
20,824
20,824
17,515
15,947
14,416
14,416
11,553
9,931
8,445
7,143
5,318
3,516
4,971
4,9713,5165,3187,1438,4459,93111,55314,41614,41615,94717,51520,82420,82423,23118,48713,9866,4376,4371,3491,3382,8254,6304,0737,3227,32210,95112,28613,70515,29016,74319,44122,12024,38225,91128,34429,64431,68234,29435,49441,60437,66434,60417,75520,00614,52216,99914,68114,58914,58913,28012,4229,5569,5568,2869,5697,4577,4573,3184,4532,1202,1201,7252,3321,2481,2481,7282,3771,2251,2258771,6222,0682,721000
       Cash And Cash Equivalents 
0
0
0
2,507
1,777
1,348
512
968
968
1,929
1,211
816
816
1,936
1,228
1,689
1,689
4,033
2,948
6,956
6,956
8,995
7,763
9,224
9,224
12,099
12,984
14,275
14,275
13,880
15,458
13,923
19,201
16,949
33,265
36,697
41,121
35,259
33,919
31,468
29,480
28,238
25,596
24,162
21,913
19,302
16,155
15,099
13,512
12,046
10,618
7,082
7,082
3,904
4,237
2,555
875
708
6,106
6,106
13,709
18,393
22,900
20,517
20,517
17,336
15,572
14,066
14,066
11,448
9,651
8,150
6,970
5,245
3,257
4,798
4,7983,2575,2456,9708,1509,65111,44814,06614,06615,57217,33620,51720,51722,90018,39313,7096,1066,1067088752,5554,2373,9047,0827,08210,61812,04613,51215,09916,15519,30221,91324,16225,59628,23829,48031,46833,91935,25941,12136,69733,26516,94919,20113,92315,45813,88014,27514,27512,98412,0999,2249,2247,7638,9956,9566,9562,9484,0331,6891,6891,2281,9368168161,2111,9299689685121,3481,7772,507000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000001,000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
66
0
0
0
115
100
91
76
62
59
45
30
17
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000173045596276911001150006600000001,000000000000000000000000000000000
       Other Current Assets 
0
0
0
214
290
274
365
0
20
171
179
0
103
128
83
0
109
107
65
0
210
210
168
332
332
323
296
314
314
802
1,542
598
805
806
1,339
150
484
235
309
214
163
106
314
219
208
140
587
190
192
240
333
240
240
169
393
270
463
641
332
277
277
94
332
0
307
179
375
0
350
105
280
0
173
72
259
0
025972173028010535003751793070332942772773326414632703931692402403332401921905871402082193141061632143092354841501,3398068055981,5428023143142963233323321682102100651071090831281030179171200365274290214000
   > Long-term Assets 
0
0
0
9
5
17
125
0
126
129
161
0
220
808
846
0
881
1,157
1,193
0
1,535
1,587
1,572
0
1,202
1,139
1,096
1,041
1,041
931
876
1,886
5,105
5,133
6,346
6,905
7,414
12,111
11,309
12,505
12,655
12,505
12,407
12,252
12,102
11,923
11,837
11,713
11,561
11,440
11,389
11,224
11,224
10,932
10,765
10,623
10,448
10,270
10,091
10,091
9,929
9,598
9,530
9,439
9,439
9,294
9,198
9,078
9,078
8,782
8,646
8,455
8,274
8,084
7,949
7,852
7,8527,9498,0848,2748,4558,6468,7829,0789,0789,1989,2949,4399,4399,5309,5989,92910,09110,09110,27010,44810,62310,76510,93211,22411,22411,38911,44011,56111,71311,83711,92312,10212,25212,40712,50512,65512,50511,30912,1117,4146,9056,3465,1335,1051,8868769311,0411,0411,0961,1391,20201,5721,5871,53501,1931,1578810846808220016112912601251759000
       Property Plant Equipment 
0
0
0
2
2
11
19
18
18
22
66
134
134
629
666
689
689
834
872
1,168
1,168
1,198
1,172
802
802
720
668
615
615
509
457
469
2,690
2,721
3,935
5,497
6,008
10,707
10,907
11,963
12,135
12,001
11,898
11,761
11,622
11,459
11,390
11,271
11,135
11,031
10,995
10,841
10,841
10,555
10,390
10,227
10,059
9,886
9,713
9,544
9,544
9,238
9,174
9,085
9,085
8,945
8,805
8,694
8,694
8,418
8,291
8,107
7,928
7,746
7,603
7,512
7,5127,6037,7467,9288,1078,2918,4188,6948,6948,8058,9459,0859,0859,1749,2389,5449,5449,7139,88610,05910,22710,39010,55510,84110,84110,99511,03111,13511,27111,39011,45911,62211,76111,89812,00112,13511,96310,90710,7076,0085,4973,9352,7212,6904694575096156156687208028021,1721,1981,1681,16887283468968966662913413466221818191122000
       Goodwill 
0
0
0
0
3
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000530000
       Intangible Assets 
0
0
0
0
0
0
5
7
7
7
7
7
7
123
180
192
192
323
321
367
367
389
400
400
403
419
428
426
426
421
419
417
415
413
410
408
406
404
402
400
398
396
394
391
389
387
385
383
381
379
377
375
375
371
369
367
365
363
360
360
358
354
352
350
350
346
344
342
342
338
336
334
332
329
327
325
3253273293323343363383423423443463503503523543583603603633653673693713753753773793813833853873893913943963984004024044064084104134154174194214264264284194034004003893673673213231921921801237777775000000
       Accumulated depreciation 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-826
-879
-931
-984
-1,037
-1,089
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,177
-3,349
-3,520
-3,693
-3,865
-4,038
-4,211
4,383
4,556
4,732
0
5,075
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000005,07504,7324,5564,383-4,211-4,038-3,865-3,693-3,520-3,349-3,177000000000000000000-1,089-1,037-984-931-879-826000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
382
389
400
400
403
419
428
426
424
0
0
1,417
0
2,413
0
0
1,406
0
402
543
521
505
0
490
0
0
447
0
0
0
0
8
7
5
6
0
0
0
0
26
63
6
4
4
4
4
49
42
0
0
0
14
0
0
0
0
000014000424944446632600006578000044700490050552154340201,406002,41301,4170042442642841940340040038938200000000000000000000
> Total Liabilities 
0
0
0
1,491
475
693
773
850
850
386
513
1,025
1,025
559
676
516
516
1,261
959
2,474
2,474
1,789
810
587
587
1,173
804
1,780
1,780
1,397
7,753
8,398
13,360
12,678
8,920
15,964
12,191
17,097
13,741
12,401
11,587
12,465
14,336
13,585
13,998
12,218
6,174
6,681
6,747
7,808
3,194
882
882
1,164
2,677
2,848
2,657
3,896
2,213
2,213
2,156
339
871
351
351
344
387
413
413
465
349
2,034
2,448
951
813
1,359
1,3598139512,4482,0343494654134133873443513518713392,1562,2132,2133,8962,6572,8482,6771,1648828823,1947,8086,7476,6816,17412,21813,99813,58514,33612,46511,58712,40113,74117,09712,19115,9648,92012,67813,3608,3987,7531,3971,7801,7808041,1735875878101,7892,4742,4749591,2615165166765591,0251,0255133868508507736934751,491000
   > Total Current Liabilities 
0
0
0
574
475
693
773
850
850
386
513
1,025
1,025
559
676
516
516
1,261
959
2,474
2,474
1,789
810
587
587
1,173
804
1,780
1,780
1,397
4,414
1,178
1,867
1,356
1,208
1,227
753
1,122
523
601
983
1,467
6,619
6,744
6,939
6,316
332
4,666
5,284
6,740
3,194
882
882
1,164
1,084
2,848
2,657
3,896
2,213
2,213
2,156
339
871
351
351
344
387
413
413
465
349
534
948
951
813
1,359
1,3598139519485343494654134133873443513518713392,1562,2132,2133,8962,6572,8481,0841,1648828823,1946,7405,2844,6663326,3166,9396,7446,6191,4679836015231,1227531,2271,2081,3561,8671,1784,4141,3971,7801,7808041,1735875878101,7892,4742,4749591,2615165166765591,0251,025513386850850773693475574000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89
159
159
1,079
633
373
3,399
0
0
0
0
9,038
0
0
0
7,181
0
0
5,271
5,475
5,689
5,911
0
3,956
4,196
1,068
902
0
123
0
0
1,646
1,224
1,062
1,181
1,181
1,145
1,108
166
0
95
0
165
0
95
0
0
0
0
0
0
0
000000095016509501661,1081,1451,1811,1811,0621,2241,6460012309021,0684,1963,95605,9115,6895,4755,271007,1810009,03800003,3993736331,07915915989000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,038
0
0
0
7,181
0
0
0
5,475
0
5,939
0
3,956
4,196
0
902
0
0
0
0
0
0
1,062
1,181
1,145
1,108
0
166
95
24
0
165
95
24
0
0
0
0
0
0
0
000000024951650249516601,1081,1451,1811,06200000090204,1963,95605,93905,4750007,1810009,03800000000000000000000000000000000000
       Accounts payable 
0
0
0
247
182
319
341
0
335
137
234
0
670
535
453
0
448
1,175
931
0
1,321
1,104
789
543
542
965
594
701
604
953
238
263
408
244
255
376
156
502
23
90
59
176
72
97
269
126
113
136
90
76
196
584
223
224
247
310
657
672
410
1,012
381
185
98
200
200
153
123
58
58
39
63
157
229
771
555
376
37655577122915763395858123153200200981853811,012410672657310247224223584196769013611312626997721765990235021563762552444082632389536047015949655425437891,1041,32109311,175448045353567002341373350341319182247000
       Other Current Liabilities 
0
0
0
327
294
375
432
0
515
249
279
0
355
23
222
0
68
86
28
0
1,152
684
21
44
45
208
210
1,176
1,176
444
4,176
915
1,459
1,111
953
851
597
620
500
511
925
1,290
650
203
120
28
219
32
20
6,664
2,998
406
659
940
838
2,538
2,000
1,371
44
1,082
69
154
24
32
24
191
99
214
260
425
286
233
719
180
259
983
98325918071923328642526021499191243224154691,082441,3712,0002,5388389406594062,9986,6642032219281202036501,2909255115006205978519531,1111,4599154,1764441,1761,1762102084544216841,152028866802222335502792495150432375294327000
   > Long-term Liabilities 
0
0
0
917
0
54,701
28,400
0
65,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,339
7,220
11,492
11,322
7,712
14,737
11,438
15,975
13,218
11,800
10,604
10,998
7,716
6,841
7,059
5,902
5,842
2,015
1,463
1,068
0
298
0
0
1,593
0
0
0
0
0
0
0
0
0
0
320
288
0
62
39
63
1,500
1,500
0
0
0
0001,5001,500633962028832000000000001,5930029801,0681,4632,0155,8425,9027,0596,8417,71610,99810,60411,80013,21815,97511,43814,7377,71211,32211,4927,2203,33900000000000000000000065,000028,40054,7010917000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,339
3,468
3,604
3,744
3,887
9,038
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000009,0383,8873,7443,6043,4683,339000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,752
7,889
7,578
3,825
10,936
9,797
9,406
6,351
4,618
3,089
3,132
4,760
3,707
3,736
2,378
2,109
2,015
1,463
1,068
0
0
0
0
1,593
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,500
0
0
0
0
00001,50000000000000000001,59300001,0681,4632,0152,1092,3783,7363,7074,7603,1323,0894,6186,3519,4069,79710,9363,8257,5787,8893,7520000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,752
7,889
7,578
3,825
5,700
9,797
0
0
4,286
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,593
0
0
0
0
12
53
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000531200001,593000000000000004,286009,7975,7003,8257,5787,8893,7520000000000000000000000000000000
> Total Stockholder Equity
0
0
0
1,238
1,598
945
228
0
500
2,120
1,376
0
444
2,582
1,895
0
2,486
4,349
3,552
0
6,519
9,367
9,049
10,171
10,171
12,388
13,572
13,850
13,850
14,215
10,122
8,010
11,751
10,211
32,029
28,605
36,827
30,508
31,861
31,786
30,712
28,384
23,982
23,048
20,225
19,146
22,406
20,322
18,519
15,918
19,146
17,664
17,664
13,841
12,717
10,600
9,130
7,722
14,315
21,758
21,758
27,746
31,890
29,911
29,911
26,465
24,758
23,082
23,082
19,870
18,228
14,866
12,969
12,451
10,652
11,464
11,46410,65212,45112,96914,86618,22819,87023,08223,08224,75826,46529,91129,91131,89027,74621,75821,75814,3157,7229,13010,60012,71713,84117,66417,66419,14615,91818,51920,32222,40619,14620,22523,04823,98228,38430,71231,78631,86130,50836,82728,60532,02910,21111,7518,01010,12214,21513,85013,85013,57212,38810,17110,1719,0499,3676,51903,5524,3492,48601,8952,58244401,3762,12050002289451,5981,238000
   Common Stock
0
0
0
109
112
112
113
0
114
119
119
0
119
123
123
0
125
132
132
0
134
139
141
144
144
150
154
156
156
161
165
47
50
50
55
55
57
57
57
57
58
58
58
58
58
58
63
63
63
63
69
69
69
70
77
77
4
4
8
9
9
11
12
12
12
12
12
12
12
12
12
0
0
0
0
0
000001212121212121212121199844777770696969636363635858585858585757575755555050471651611561561541501441441411391340132132125012312311901191191140113112112109000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-24,357
-25,748
-27,780
-29,424
-31,228
-32,436
36,119
-38,300
44,573
46,265
46,559
52,406
-51,050
-52,931
-53,182
-54,100
-55,407
-58,182
-63,173
-64,824
-67,886
-69,432
-72,571
-75,129
-77,134
-79,931
-82,041
-83,692
-85,534
-87,765
-89,904
-92,117
-93,678
-95,605
-103,689
-105,563
-107,874
-110,204
-112,312
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000-112,312-110,204-107,874-105,563-103,689-95,605-93,678-92,117-89,904-87,765-85,534-83,692-82,041-79,931-77,134-75,129-72,571-69,432-67,886-64,824-63,173-58,182-55,407-54,100-53,182-52,931-51,05052,40646,55946,26544,573-38,30036,119-32,436-31,228-29,424-27,780-25,748-24,357000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
-8
-8
0
0
-15
-15
0
0
-96
-96
0
0
-615
-615
0
0
-826
-826
-931
-984
-1,037
-1,089
-1,138
-1,189
-1,240
-1,291
-1,343
-1,394
-1,534
-1,696
-1,527
-1,691
-1,851
-2,014
-2,177
-2,340
-2,506
-2,672
-2,838
-3,007
-3,177
-3,177
-3,520
-3,693
-3,865
-4,038
-4,211
-4,383
-4,383
-4,556
-4,901
144,202
0
0
0
0
0
-12
0
0
0
0
0
0
0
0000000-1200000144,202-4,901-4,556-4,383-4,383-4,211-4,038-3,865-3,693-3,520-3,177-3,177-3,007-2,838-2,672-2,506-2,340-2,177-2,014-1,851-1,691-1,527-1,696-1,534-1,394-1,343-1,291-1,240-1,189-1,138-1,089-1,037-984-931-826-82600-615-61500-96-9600-15-1500-8-800000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,589
37,978
41,189
43,109
43,856
46,481
46,066
46,259
56,271
56,423
78,531
80,953
83,179
83,379
84,983
85,825
86,057
86,504
87,093
87,810
88,048
88,515
94,909
95,383
95,586
95,782
101,114
101,283
101,437
101,531
102,540
102,635
102,803
103,323
117,995
127,312
137,846
137,939
144,190
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000144,190137,939137,846127,312117,995103,323102,803102,635102,540101,531101,437101,283101,11495,78295,58695,38394,90988,51588,04887,81087,09386,50486,05785,82584,98383,37983,17980,95378,53156,42356,27146,25946,06646,48143,85643,10941,18937,97835,589000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
4,480
5,576
5,613
5,814
0
6,856
9,425
9,472
0
9,540
13,042
13,143
0
14,370
17,869
19,489
0
23,213
28,633
30,858
0
33,851
37,978
41,189
0
43,935
47,412
47,050
47,296
57,360
57,561
79,720
82,193
90,704
84,722
86,377
87,359
87,752
88,031
88,784
89,661
90,063
90,692
97,249
97,888
98,257
98,620
104,121
0
104,460
105,051
106,233
106,500
106,841
107,534
122,379
0
131,868
142,840
-12
0
144,285
145,373
145,458
0
145,562
145,666
145,727
0
146,018
147,615
147,670
150,839
150,839147,670147,615146,0180145,727145,666145,5620145,458145,373144,2850-12142,840131,8680122,379107,534106,841106,500106,233105,051104,4600104,12198,62098,25797,88897,24990,69290,06389,66188,78488,03187,75287,35986,37784,72290,70482,19379,72057,56157,36047,29647,05047,41243,935041,18937,97833,851030,85828,63323,213019,48917,86914,370013,14313,0429,54009,4729,4256,85605,8145,6135,5764,480000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-759
Gross Profit-759-759
 
Operating Income (+$)
Gross Profit-759
Operating Expense-8,516
Operating Income-8,516-9,275
 
Operating Expense (+$)
Research Development5,437
Selling General Administrative3,079
Selling And Marketing Expenses0
Operating Expense8,5168,516
 
Net Interest Income (+$)
Interest Income272
Interest Expense-50
Other Finance Cost-0
Net Interest Income222
 
Pretax Income (+$)
Operating Income-8,516
Net Interest Income222
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-8,294-8,738
EBIT - interestExpense = -8,566
-8,294
-8,244
Interest Expense50
Earnings Before Interest and Taxes (EBIT)-8,516-8,244
Earnings Before Interest and Taxes (EBITDA)-7,757
 
After tax Income (+$)
Income Before Tax-8,294
Tax Provision-0
Net Income From Continuing Ops-8,294-8,294
Net Income-8,294
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses8,516
Total Other Income/Expenses Net222-222
 

Technical Analysis of Nanoviricides
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nanoviricides. The general trend of Nanoviricides is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nanoviricides's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NanoViricides Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.33 < 1.33 < 1.58.

The bearish price targets are: 1.2 > 1.1 > 1.1.

Tweet this
NanoViricides Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NanoViricides Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NanoViricides Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NanoViricides Inc. The current macd is -0.04771242.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nanoviricides price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nanoviricides. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nanoviricides price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
NanoViricides Inc Daily Moving Average Convergence/Divergence (MACD) ChartNanoViricides Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NanoViricides Inc. The current adx is 17.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nanoviricides shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
NanoViricides Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NanoViricides Inc. The current sar is 1.46398234.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NanoViricides Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NanoViricides Inc. The current rsi is 45.28. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
NanoViricides Inc Daily Relative Strength Index (RSI) ChartNanoViricides Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NanoViricides Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nanoviricides price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NanoViricides Inc Daily Stochastic Oscillator ChartNanoViricides Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NanoViricides Inc. The current cci is -74.3093159.

NanoViricides Inc Daily Commodity Channel Index (CCI) ChartNanoViricides Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NanoViricides Inc. The current cmo is -6.78686214.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NanoViricides Inc Daily Chande Momentum Oscillator (CMO) ChartNanoViricides Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NanoViricides Inc. The current willr is -63.15789474.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nanoviricides is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NanoViricides Inc Daily Williams %R ChartNanoViricides Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NanoViricides Inc.

NanoViricides Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NanoViricides Inc. The current atr is 0.09514443.

NanoViricides Inc Daily Average True Range (ATR) ChartNanoViricides Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NanoViricides Inc. The current obv is 11,972,784.

NanoViricides Inc Daily On-Balance Volume (OBV) ChartNanoViricides Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NanoViricides Inc. The current mfi is 29.52.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
NanoViricides Inc Daily Money Flow Index (MFI) ChartNanoViricides Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NanoViricides Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

NanoViricides Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NanoViricides Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.284
Ma 20Greater thanMa 501.391
Ma 50Greater thanMa 1001.443
Ma 100Greater thanMa 2001.689
OpenGreater thanClose1.270
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Nanoviricides with someone you think should read this too:
  • Are you bullish or bearish on Nanoviricides? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nanoviricides? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NanoViricides Inc

I send you an email if I find something interesting about NanoViricides Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NanoViricides Inc.

Receive notifications about NanoViricides Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.